This June, our researchers and physicians joined colleagues from around the world at the annual ASCO meeting in Chicago. This year’s program featured over 200 sessions complementing the meeting’s theme: Advancing Equitable Cancer Care Through Innovation. View full conference information and abstract titles.
Below are notable sessions featuring our faculty and fellows this year (see full listings of presenters at the links provided).
Cancer: Common Humanity, Different Worlds
Speaker: Kevin Diasti, MD, fellow, Department of Medicine, Division of Hematology and Medical Oncology
Location: Arie Crown Theater
Doubling Down on Immunotherapy
Speaker: Kristen Renee Spencer, DO, MPH, director, Phase I Program, Laura and Isaac Perlmutter Cancer Center at NYU, assistant professor of medicine, NYU Grossman School of Medicine
Experiences of researchers fulfilling VHA’s “fourth mission” during the COVID-19 pandemic.
Presenter: Kenneth Csehak, MD, fellow, Department of Medicine, Division of Hematology and Medical Oncology
Safety and efficacy of daratumumab use in patients with renal impairment and hemodialysis.
Presenter: Mateusz Niewinski, BA, BPS, PharmD, pharmacy resident, NYU Langone Health
Endometrial Cancer Barriers in the LGBTQ Community
Speaker: Gwendolyn Quinn, PhD, the Livia S. Wan, M.D. Professor of Obstetrics and Gynecology, professor, Department of Population Health
Location: E253b | In-Person Only
TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.
Presenter: Benjamin Thomas Cooper, MD, assistant professor, Department of Radiation Oncology
BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy.
Presenter: Diane M. Simeone, MD, the Laura and Isaac Perlmutter Professor of Surgery, Departments of Surgery and Pathology
Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.
Presenter: Nina Beri, MD, clinical assistant professor, Department of Medicine at NYU Grossman School of Medicine, medical oncologist, Perlmutter Cancer Center
Examination of speakership gender disparity at an international oncology conference.
Presenter: Jessica Caro, MD, chief fellow, Department of Medicine, Division of Hematology and Medical Oncology
PD-1 Plus X: Which Combinations in Early Development Are Showing the Most Promise?
Presenter: Janice Mehnert, MD, professor, Department of Medicine, Division of Hematology and Medical Oncology
Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.
Presenter: Joshua K. Sabari, MD, assistant professor, Department of Medicine, Division of Hematology and Medical Oncology
Location: Hall D1
Racial concordance and trust in health communications: A randomized trial of videos about prostate cancer.
Presenter: Stacy Loeb, MD, professor, Departments of Urology, and Population Health
Location: Arie Crown Theater
A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer (NSCLC): SYMPHONY trial in progress.
Presenter: Elaine Shum, MD, assistant professor, Department of Medicine, Division of Hematology and Medical Oncology
What is driving declines in oncology-prescribed opioids?
Presenter: Tarlise Townsend, PhD, postdoctoral fellow, Department of Population Health, Division of Epidemiology, NYU Langone Health Center for Opioid Epidemiology & Policy
ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.
Presenter: Jeffrey S. Weber, MD, PhD, the Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, Division of Hematology and Medical Oncology
A phase 1/2 multicenter investigator-initiated trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Presenter: David R. Wise, MD, PhD, assistant professor, Department of Medicine, Division of Hematology and Medical Oncology, and Department of Urology